

## Erratum to: $^{18}\text{F}$ -Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

Ugo De Giorgi<sup>1</sup> · Paola Caroli<sup>2</sup> · Emanuela Scarpi<sup>3</sup> · Vincenza Conteduca<sup>1</sup> ·  
Salvatore Luca Burgio<sup>1</sup> · Cecilia Menna<sup>1</sup> · Andrea Moretti<sup>4</sup> · Riccardo Galassi<sup>4</sup> ·  
Lorena Rossi<sup>1</sup> · Dino Amadori<sup>1</sup> · Giovanni Paganelli<sup>2</sup> · Federica Matteucci<sup>2</sup>

Published online: 22 April 2015  
© Springer-Verlag Berlin Heidelberg 2015

**Erratum to: Eur J Nucl Med Mol Imaging**  
**DOI 10.1007/s00259-015-3042-5**

Owing to an error in typesetting, a table that should have been presented as part of Table 2 was separated from Table 2 and placed on an earlier page. The correct and complete Table 2 is reproduced here.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00259-015-3042-5>.

---

✉ Ugo De Giorgi  
[ugo.degiorgi@irst.emr.it](mailto:ugo.degiorgi@irst.emr.it)

<sup>1</sup> Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Maroncelli 40, 47014 Meldola, Italy

<sup>2</sup> Diagnostic Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

<sup>3</sup> Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

<sup>4</sup> Nuclear Medicine Unit, Morgagni-Pierantoni Hospital, Forlì, Italy

**Table 2** Comparison of PSA decline and FCH PET/CT in non-progressing vs progressing patients

Response at Follow-up FCH PET/CT Imaging Study	PSA Response PSA decline $\geq 50$ %	No PSA decline $\geq 50$ %	Total
NonProgression <sup>a</sup>	10 (59 %)	7 (41 %)	17 (50 %)
Progression	3 (18 %)	14 (82 %)	17 (50 %)
Total	13 (38 %)	21 (62 %)	34 (100 %)
Measurement	Estimate	Lower 95 % CI	Upper 95 % CI
Positive % Agreement	67 %	48 %	81 %
Negative % Agreement	77 %	59 %	89 %
Positive Predictive Value	82 %	65 %	93 %
Negative Predictive Value	59 %	41 %	75 %
Overall Agreement	71 %	55 %	86 %
Odds Ratio	6.7	1.38	32.3

<sup>a</sup> Including 7 pts with partial response (PR) and 10 with stable disease (SD) at FCH PET/CT, achieving a PSA response in 4/7 (57 %) PR and 6/10 (60 %) SD cases, respectively

Measurement Agreement (%)	Estimate	95 % CI
Positive	67 %	48–81 %
Negative	77 %	59–89 %
Predictive value		
Positive	82 %	65–93 %
Negative	59 %	41–75 %
Overall agreement	71 %	55–86 %
Odds ratio	6.7	1.38